| Authors: |
Marques DF; Epiconcept, Paris, France.; NOVA National School of Public Health, Public Health Research Centre, Comprehensive Health Research Center, NOVA University Lisbon, Lisbon, Portugal., Kovacs D; Epiconcept, Paris, France., Sanchez-Ruiz MA; Epiconcept, Paris, France., Rodrigues AP; Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal., Machado A; Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal., Mazagatos C; Communicable Diseases Department, National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain.; CIBERESP, Madrid, Spain., Monge S; Communicable Diseases Department, National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain.; CIBERINFEC, Madrid, Spain., Domegan L; HSE Health Protection Surveillance Centre, Dublin, Ireland., O'Donnell J; HSE Health Protection Surveillance Centre, Dublin, Ireland., Hooiveld M; Nivel, Utrecht, the Netherlands., Emborg HD; Statens Serum Institut, Copenhagen, Denmark., Nunes B; Epiconcept, Paris, France.; NOVA National School of Public Health, Public Health Research Centre, Comprehensive Health Research Center, NOVA University Lisbon, Lisbon, Portugal., Carvalho C; European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden., Rose AM; Epiconcept, Paris, France. |
